PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

PCI Pharma Services Announces Serialization Installation at Tredegar Manufacturing Center of Excellence

PCI’s Tredegar site is the latest site to offer full Serialization services to global customers   
 PCI Pharma Services (PCI) is pleased to announce the installation and validation of its latest comprehensive Serialization system, located at its manufacturing Center of Excellence in Tredegar, UK.  The investment demonstrates PCI’s continued investment in and expansion of market-leading Serialization capabilities. This latest installation increases PCI’s Serialization capability to support clients in advance of implementation dates for the European Falsified Medicines Directive (EU FMD), as well as supply for the US and emerging markets, including countries such as China, Turkey, Brazil, Saudi Arabia and others.  PCI’s system is compliant to all EU member country requirements for Serialization and specialized labeling, including application and integration of advanced Anticounterfeiting technologies.
The highly flexible technology delivers machine and human-readable coding, tamper evident solutions and Bollini labeling – which in turn is linked to a case loading and aggregation station, with a final aggregation station connecting cases to pallet. PCI is a strong supporter of the advanced use of aggregation to support product security, realizing the significant benefits in packaging operations, as well as the broader pharmaceutical supply chain.
PCI’s site in Tredegar, South Wales, UK already offers excellence in potent manufacturing services for customers globally, and this new Serialization technology further strengthens its comprehensive offering. This investment in the Tredegar facility is part of a significant global initiative to develop the Serialization services across PCI’s global network, which will ultimately exceed more than 90 lines.
Commenting on this latest investment, Jim Neville, Director of Operations, Tredegar, stated: “This is an important addition to the site’s capabilities. Being able to offer this fully flexible service and work in partnership with our customers to deliver a trusted, seamless service is critical, and being ahead of the timelines with this offering ensures compliance with the EU FMD.”
PCI has been actively Serializing commercial products for the US, European and international markets for the past six years, and this investment in the Tredegar capabilities continues to demonstrate PCI’s market-leading position. The integrated technology strategy enables operators in all PCI’s global locations to operate the same graphical user interface, providing a seamless global service.  PCI clients enjoy singular connectivity to all PCI sites through a best-in-class platform.  PCI is dedicated to maintaining a leadership position at the forefront of the Serialization initiative and providing clients with an industry-leading customer experience.
 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026